Avantium Technologies Announces Collaboration with GlaxoSmithKline
News Apr 21, 2006
Avantium Technologies have announced that they have a collaboration with GlaxoSmithKline for the extensive screening of several GSK pharmaceutical compounds utilizing Avantium’s high-throughput polymorph, salt and co-crystal screening capabilities to find novel solid forms.
Avantium Technologies is an innovation-based company and its unique integrated screening platform provides a fast and efficient way to explore a wide array of crystallization conditions to generate and identify novel solid forms.
“We welcome this great opportunity to collaborate with GlaxoSmithKline,” said Guus Scheefhals, Chief Business Officer of Avantium Technologies. “It is an honor to contribute to the development of GSK’s therapeutic products by using our highthroughput technology platform and rational experimental design strategy. This intensive partnership is a valuable recognition of our capabilities.“
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE